Discovery and SAR of PF-4693627, a potent, selective and orally bioavailable mPGES-1 inhibitor for the potential treatment of inflammation

Bioorganic and Medicinal Chemistry Letters

Volumn 23, Issue 4, 2013, Pages 1114-1119

  Arhancet, Graciela B ^a   Walker, Daniel P ^a   Metz, Sue ^a   Fobian, Yvette M ^a   Heasley, Steven E ^a   Carter, Jeffrey S ^a   Springer, John R ^a   Jones, Darin E ^a   Hayes, Michael J ^a   Shaffer, Alexander F ^a   Jerome, Gina M ^a   Baratta, Michael T ^a   Zweifel, Ben ^a   Moore, William M ^a   Masferrer, Jaime L ^a   Vazquez, Michael L ^a  

^a PFIZER INC   (United States)

Author keywords

Benzoxazole; Clinical candidate; Inflammation; m PGES 1; PF 4693627

Indexed keywords

ANTIINFLAMMATORY AGENT; CARRAGEENAN; CYCLOOXYGENASE 2; NAPROXEN; PF 4693627; PROSTAGLANDIN E SYNTHASE 1; UNCLASSIFIED DRUG;

ARTICLE; DRUG BIOAVAILABILITY; EXPERIMENTAL GUINEA PIG; INFLAMMATION; STRUCTURE ACTIVITY RELATION;

ANTI-INFLAMMATORY AGENTS; DRUG DISCOVERY; ENZYME INHIBITORS; HUMANS; INFLAMMATION; INTRAMOLECULAR OXIDOREDUCTASES; STRUCTURE-ACTIVITY RELATIONSHIP;

CAVIA;

EID: 84872946941     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2012.11.109     Document Type: Article

References (23)

1. T.A. Samad, K.A. Moore, A. Sapirstein, S. Billet, A. Allorhorme, S. Poole, J.V. Bonventre, and C.J. Woolf Nature 410 2001 471
2. C.D. Funk Science 2001 1871 294
3. T. Kobayashi, and S. Narumiya Prostaglandins Other Lipid Mediators 2002 68
4. J.L. Goulet, A.J. Pace, M.L. Key, R.S. Byrum, M. Nguyen, S.L. Tilley, S.G. Morham, R. Langenbach, J.L. Stock, J.D. McNeish, and O. Smithies J. Immunol. 173 2004 1321
5. S.M. Jachak Curr. Opin. Investig. Drugs 8 2007 411
6. C. Brenneis, O. Coste, R. Schmidt, C. Angioni, L. Popp, R.M. Nusing, W. Becker, K. Scholich, and G. Geisslinger J. Cell Mol. Med. 12 2008 639
7. R.W. Friesen, and J.A. Mancini J. Med. Chem. 51 2008 4059
8. D. Riendeau, R. Aspiotis, D. Ethier, Y. Gareau, E.L. Grimm, J. Guay, S. Guiral, H. Juteau, J.A. Mancini, N. Methot, J. Rubin, and R.W. Friesen Bioorg. Med. Chem. Lett. 15 2005 3352
9. Pelcman, B.; Olofsson, K.; Schaal, W.; Kalvins, I.; Katkevics, M.; Ozola, V.; Suna, E. PCT Int. Appl. WO 2007042816, 2007.
10. B. Coté, L. Boulet, C. Brideau, D. Claveau, D. Ethier, R. Frenette, M. Gagnon, A. Giroux, J. Guay, S. Guiral, J. Mancini, E. Martins, F. Massé, N. Methot, D. Riendeau, J. Rubin, D. Xu, H. Yu, Y. Ducharme, and R.W. Friesen Bioorg. Med. Chem. Lett. 17 2007 6816 6820
11. Kablaoui, N.; Patel, S.; Shao, J.; Demian, D.; Hoffmaster, K.; Berlioz, F.; Vazquez, M. L.; Moore, W. M.; Nugent, R. A. http://dx.doi.org/10.1016/j.bbr. 2011.03.031.
12. J. Wang, D. Limburg, J. Carter, G. Mbalaviele, J. Gierse, and M. Vazquez Bioorg. Med. Chem. Lett. 2010 1604
13. For the synthesis of the amino alcohols contained in compounds 10-12, see: D.P. Walker, S.E. Heasley, A. MacInnes, T. Anjeh, H.-F. Lu, Y.M. Fobian, J.T. Collins, M.L. Vazquez, and M.K. Mao Synlett 2011 2959
14. A detailed study looking at the conformation analysis of the 1,4- and 1,3-disubstituted cyclohexane analogs is published in the adjoining paper.
15. 50 was generally less than 30%.
16. Assay conditions adopted from published protocols, see: R.J. Riley, D.F. McGinnity, and R.P. Austin Drug Metab. Dispos. 33 2005 1304
17. R.S. Obach Drug Metab. Dispos. 27 1999 1350
18. N.A. Hosea, W.T. Collard, S. Cole, T.S. Maurer, R.X. Fang, H. Jones, S.M. Kakar, Y. Nakai, B.J. Smith, R. Webster, and K. Beaumont J. Clin. Pharmacol. 49 2009 513
19. N. Miyaura, T. Ishiyama, M. Ishikawa, and A. Suzuki Tetrahedron Lett. 1986 6369
20. Q. Chen, and S. Wu J. Chem. Soc., Chem. Commun. 1989 705
21. J.C. Duff, and E.J. Bills J. Chem. Soc. 1932 1987
22. 80 values for each experiment were calculated using a four-parameter sigmoid model. Naproxen was used as a reference compound at 10 mg/kg.
23. 2 was added to the cells 40 min after addition of the compounds (or 10 min before addition of arachidonic acid). PG levels in the supernatants were assayed by ELISA.